chloroquin
hydroxychloroquin
wide
use
antimalari
drug
immunomodulatori
properti
approv
use
number
rheumatolog
diseas
antivir
effect
discov
relat
abil
limit
viral
replic
increas
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
key
regul
endocytosi
baricitinib
seem
inhibit
bind
cyclin
gassoci
kinas
gak
anoth
regul
endocytosi
thu
block
viral
entri
rheumatologist
know
effect
drug
also
vital
aspect
safeti
although
imper
need
discov
treatment
save
human
live
infect
also
necessari
consid
possibl
advers
effect
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
pdf
file
articl
undergon
enhanc
accept
addit
cover
page
metadata
format
readabl
yet
definit
version
record
version
undergo
addit
copyedit
typeset
review
publish
final
form
provid
version
give
earli
visibl
articl
pleas
note
product
process
error
may
discov
could
affect
content
legal
disclaim
appli
journal
pertain
threaten
resili
nation
health
system
inevit
rais
question
world
polit
economicfinanci
futur
diseas
phenotyp
present
patient
may
asymptomat
mild
symptom
whose
clinic
pictur
may
extrem
sever
lead
death
although
everi
effort
made
develop
effect
vaccin
prophylact
treatment
soon
possibl
order
manag
infect
prevent
futur
epidem
even
two
previou
coronaviru
epidem
found
unprepar
current
manag
strategi
aim
reduc
transmiss
infect
provid
support
hospit
patient
variou
drug
empir
use
basi
vitro
antivir
antiinflammatori
properti
except
case
report
still
concret
evid
safe
efficaci
coronaviru
includ
sar
midst
pandem
rheumatologist
play
import
role
collect
address
impact
viru
vulner
popul
rheumat
diseas
also
popul
whole
may
expert
infecti
diseas
coronavirus
consider
knowledg
expertis
concern
drug
current
test
treatment
old
acquaint
chloroquin
hydroxychloroquin
tocilizumab
inhibitor
agent
indic
differ
rheumat
diseas
ideal
place
share
experi
rest
scientif
commun
endosom
ph
requir
viruscel
fusion
thu
inhibit
tolllik
receptor
activ
interf
receptor
anecdot
report
success
chloroquin
treatment
china
guidelin
italian
societi
infecti
tropic
diseas
simit
suggest
use
case
mild
form
question
whether
chloroquin
hydroxychloroquin
play
prophylact
role
randomis
doubleblind
placebocontrol
clinic
trial
chloroquin
found
prevent
influenza
infect
clinic
present
differ
rang
influenzalik
symptom
fever
cough
dyspnea
nausea
vomit
diarrhea
sever
form
diffus
interstiti
pneumonia
specif
radiograph
pattern
characteris
neutrophilia
lymphopenia
thrombocytopenia
high
level
acut
phase
reactant
inflammatori
cytokin
includ
acut
respiratori
distress
syndrom
induc
coronaviru
infect
associ
overexuber
releas
cytokin
cytokin
storm
sar
mer
patient
peak
viral
load
preced
maximum
releas
subsequ
radiograph
sever
pneumonia
also
pyrogen
cytokin
trial
involv
patient
china
found
tocilizumab
receptor
antagonist
quickli
resolv
clinic
manifest
fever
oxygen
satur
sarilumab
inhibitor
solubl
membran
receptor
may
reduc
sever
pulmonari
complic
includ
respiratori
failur
evid
antivir
potenti
clinic
trial
underway
aim
demonstr
efficaci
two
drug
sever
form
like
play
key
role
hyperinflamm
hypothesis
use
blocker
possibl
therapeut
strategi
may
role
janu
kinas
inhibitor
baricitinib
treatment
acut
respiratori
diseas
virus
infect
cell
mean
endocytosi
protein
kinas
peopl
affect
infect
adult
age
year
one
concomit
medic
condit
cardiovascular
hepat
renal
andor
bone
marrow
comorbid
neutropenia
hepat
increas
hepat
enzym
qt
prolong
bone
marrow
dysfunct
possibl
manifest
potenti
advers
event
chloroquin
hydroxychloroquin
tocilizumab
sarilumab
agent
steroid
agent
may
lead
profound
immunosuppress
increas
risk
infect
agent
also
associ
bacteri
pneumonia
gastrointestin
perfor
care
screen
therefor
necessari
start
treatment
use
experienc
physician
rheumatologist
alway
work
vulner
immunocompromis
patient
high
risk
infect
therefor
highli
experienc
protect
advers
effect
immunosuppress
treatment
last
least
rheumatologist
specif
respons
ensur
patient
appropri
manag
burden
nation
health
servic
littl
possibl
given
high
risk
use
suggest
altern
manag
method
delay
routin
medic
appoint
promot
telework
develop
app
monitor
condit
boat
toss
sea
pandem
uncertainti
fear
today
ever
way
reach
side
ensur
solid
collabor
physician
scientist
politician
